Get the Stockscreener App
4.69
0.43%
0.02
After Hours:
4.82
0.13
+2.77%
Vanda Pharmaceuticals Inc stock is traded at $4.69, with a volume of 396.04K.
It is up +0.43% in the last 24 hours and down -11.34% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
See More
Previous Close:
$4.67
Open:
$4.63
24h Volume:
396.04K
Relative Volume:
0.62
Market Cap:
$271.63M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
17.37
EPS:
0.27
Net Cash Flow:
$12.42M
1W Performance:
-1.26%
1M Performance:
-11.34%
6M Performance:
+14.11%
1Y Performance:
+8.56%
1-Day Range:
$4.61
$4.73
1-Week Range:
$4.61
$5.13
52-Week Range:
$3.295
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Vanda Pharmaceuticals (NASDAQ:VNDA) Receives New Coverage from Analysts at StockNews.com - MarketBeat
DC Circ. Judges Ask If It's Too Late To Fast-Track Gastro Drug - Law360
DC Circuit Weighs FDA's Fast-Track Denial For Vanda Stomach Drug - Bloomberg Law
StockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Renaissance Technologies LLC Reduces Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis - Yahoo Finance
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis - Zacks Investment Research
FDA declines approval for Vanda’s gastroparesis treatment - Pharmaceutical Technology
Items Tagged with 'Vanda Pharmaceutical Inc.' - BioWorld Online
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today - MSN
US FDA issues CRL for Vanda’s tradipitant for gastroparesis - BioWorld Online
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today - The Motley Fool
Vanda Pharmaceuticals decries FDA’s rejection of stomach paralysis drug as unjust - Invezz
Vanda Pharmaceuticals decries FDA’s rejection of stomach paralysis drug as unjust - TradingView
FDA snubs Vanda Pharma's NDA for tradipitant in gastroparesis - The Pharma Letter
FDA declines Vanda Pharmaceuticals' gastroparesis drug By Investing.com - Investing.com Australia
FDA declines Vanda Pharmaceuticals' gastroparesis drug - Investing.com India
US FDA declines to approve Vanda's stomach condition drug - Yahoo Finance
FDA rejects Vanda Pharmaceuticals' application to bring key drug to market - The Business Journals
FDA declines Vanda Pharmaceuticals' gastroparesis drug - Investing.com
D.C. Federal Judge Punts Challenge To Generic Drug Approval Until FDA Ruling - Law360
FDA declines Vanda Pharmaceuticals' gastroparesis drug By Investing.com - Investing.com Canada
Vanda stock slips after FDA snub for therapy (NASDAQ:VNDA) - Seeking Alpha
FDA Rejects Vanda Pharma's Application for Gastroparesis Drug Tradipitant - Morningstar
FDA Rejects Vanda Pharma's Application for Gastroparesis Drug Tradipitant - MarketWatch
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis - StockTitan
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
In the Green: Vanda Pharmaceuticals Inc (VNDA) Closes at 4.94, Up/Down -2.76 from Previous Day - The Dwinnex
Vanda Pharmaceuticals Inc (VNDA) may enjoy gains as insiders got busy in the recent days - Knox Daily
Dentalcorp Holdings Ltd (DNTL-T) QuotePress Release - The Globe and Mail
FDA Decision Due on Vanda Pharma's Gastroparesis Drug - MarketWatch
Viking Therapeutics Inc (VKTX) gets rating Initiated from JP Morgan - Knox Daily
Ivanhoe Electric Inc (IE-T) QuotePress Release - The Globe and Mail
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. - The Motley Fool
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat
Why Investors Plowed Into Viking Therapeutics Stock Today - The Motley Fool
After Roche data, Morgan Stanley says Viking VK2735 has best-in-class potential - TipRanks
Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference - Longview News-Journal
Acadian Asset Management LLC Lowers Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Judge Tosses Vanda Generic Sleep Drug Approval Suit Against FDA - Bloomberg Law
192,926 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Purchased by Monaco Asset Management SAM - MarketBeat
Medicenna Therapeutics Corp (MDNA-T) QuotePress Release - The Globe and Mail
StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids - Seeking Alpha
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference - StockTitan
Vanda Pharmaceuticals Sues FDA Over New Drug Approval Structure - Bloomberg Law
Biotech Stocks Facing FDA Decision In September 2024 - Nasdaq
Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference - PR Newswire
(VNDA) Investment Analysis and Advice - Stock Traders Daily
Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference - Longview News-Journal
Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):